

Experimental
ATHERO-
SCLEROSIS

LOUIS N. KATZ, M.D.
JEREMIAH STAMLER, M.D.

experimental **ATHEROSCLEROSIS**

By

LOUIS N. KATZ, M.D.

Director, Cardiovascular Department
Medical Research Institute, Michael Reese Hospital
Professorial Lecturer in Physiology
University of Chicago
Chicago, Illinois

and

JEREMIAH STAMLER, M.D.

Research Associate, Cardiovascular Department
Medical Research Institute, Michael Reese Hospital
Chicago, Illinois
Established Investigator
American Heart Association



CHARLES C THOMAS • PUBLISHER
Springfield • Illinois • U.S.A.

CHARLES C THOMAS • PUBLISHER
BANNERSTONE HOUSE
301-327 East Lawrence Avenue, Springfield, Illinois, U.S.A.

Published simultaneously in the British Commonwealth of Nations by
BLACKWELL SCIENTIFIC PUBLICATIONS, LTD., OXFORD, ENGLAND

Published simultaneously in Canada by
THE RYERSON PRESS, TORONTO

This monograph is protected by copyright. No
part of it may be reproduced in any manner
without written permission from the publisher.

Copyright, 1953, by CHARLES C THOMAS • PUBLISHER

Printed in the United States of America

experimental
ATHEROSCLEROSIS

Publication Number 124
AMERICAN LECTURE SERIES

A Monograph in
The BANNERSTONE DIVISION of
AMERICAN LECTURES IN METABOLISM

Edited by
PAUL GYÖRGY, M.D.
Department of Pediatrics
University of Pennsylvania School of Medicine
Philadelphia, Pennsylvania

LOUIS LEITER, M.D., Ph.D.
Division of Medicine
Montefiore Hospital
New York, New York

S. O. WAIFE, M.D.
Lilly Research Laboratories
Indianapolis, Indiana

To the Memory of
Deborah V. Dauber, M.D.

ACKNOWLEDGMENTS

OVER THE YEARS A LARGE GROUP OF PHYSICIANS PARTICIPATED in the atherosclerosis research program of this department, contributing in a major way to its execution. Particularly do we wish to pay tribute to Deborah V. Dauber, M.D., whose untimely death in 1946 prematurely interrupted a fruitful career in atherosclerosis research. Following in Dr. Dauber's footsteps in the atherosclerosis research team, Louis Horlick, M.D. made a further significant contribution in leadership and content, during his tenure in the department. More recently, the leading personnel of our atherosclerosis team has been further strengthened by the contribution of Ruth Pick, M.D. It is gratifying that the Assistant Director of the Department, Simon Rodbard, M.D., Ph.D., who acted over the years in an administrative and advisory capacity in the development of this program, has latterly become an active, immediate participant in atherosclerosis research. We wish also to acknowledge the work of Drs. Leonard C. Akman, Sidney A. Carlen, Maurice Feldman, Jr., Gerald Graham, Gerard Gros, Raymond Harris, Milton Hurwitz, Martin Lowenthal, Raymond S. Megibow, Albert J. Miller, Giuseppe Mininni, Alexander Sanders, Jakub G. Schlichter and Earl N. Silber. Several members of other departments of the Michael Reese Hospital have aided us in various projects, among them Dr. Robert A. Arens, X-Ray Department; Dr. David Cohn and Dr. Clarence Cohn, Department of Biochemistry; Dr. Rachmiel

Levine, Department of Metabolic and Endocrine Research; Dr. Otto Saphir, Department of Pathology; Dr. Herbert Silverstone, Department of Cancer Research.

An indispensable contribution to our research has been made by the able group of research assistants and technicians participating in the atherosclerosis research team. Without their intelligent and skillful cooperation our program of investigation could not have been consummated. We gratefully acknowledge the services of Lorraine Adams, Eileen Arnold, Phyllis Bland, Christine Bolene-Williams,* Grady Crowley, Marilyn Dudley, William Foote, Louise Friedberg, Dolores Friedman, Lillian Havel,* Phillip Johnson, Eva Levinson and Julia Meyer. We wish further to express our great appreciation to Dolores Friedman for her diligent and patient assistance, beyond the call of duty, in preparing the Tables, Bibliography and Indices of this monograph. We also are grateful to Hiroshi Saiki, who prepared the figures, and to the department's secretaries during the preparation of this monograph, Madge French, Rivian Lewin, Edith L. Lirtzman, Barbara Liss, Rita Nagel and Florence F. Orner. Further we acknowledge with thanks the many services rendered us by the Medical Research Institute librarians, Lise Giraud, Bernice Ortlepp and Marion Stevenson. We acknowledge with thanks the aid of Mrs. Rose Stamler in compiling the Indices.

Our research work was further aided by the cooperation of several pharmaceutical houses and their research staffs, including Associated Concentrates, Inc., Long Island, New York; Armour Laboratories, Chicago, Illinois; Lederle Laboratories, Pearl River, New York; Lilly Laboratory for Clinical Research, Indianapolis, Indiana; Merck and Company, Inc., Rahway, New Jersey; Schering Corp., Bloomfield, New Jersey; The Upjohn Company, Kalamazoo, Michigan; Vio Bin Corp., Monticello, Illinois; The Wilson Labora-

*Deborah V. Dauber Memorial Research Assistant.

ACKNOWLEDGMENTS

tories, Chicago, Illinois; Winthrop-Stearns, Inc., New York, New York; and Wyeth, Inc., Philadelphia, Pennsylvania.

Finally, the research program of this department on experimental atherosclerosis was made possible only by the grants-in-aid awarded it, principally from the Life Insurance Medical Research Fund and the National Heart Institute of the United States Public Health Service, and also from the Special Cardiac Fund of the Committee on Scientific Research, American Medical Association; the Chicago Heart Association; the Sam and Sarah Ehrlich Memorial Fund; the A.B. Kuppenheimer Fund; the E.J. Loewenthal Fund; the Herbert G. Mayer Memorial Fund; the Michael Reese Research Foundation; the Nelson Morris Fund; the Jeanette N. and Alex D. Nast Fund for Cardiovascular Research; and the Emil and Fanny Wedeles Fund and latterly by the American Heart Association.

The cooperation of the staff of the publisher, Charles C Thomas, in the preparation of the finished monograph is gratefully acknowledged. We also appreciate the generosity of authors and publishers who granted permission to quote their work and to reproduce some of the tables and figures presented in this monograph.

L.N.K.

J.S.

Chicago, Illinois

experimental
ATHEROSCLEROSIS

CONTENTS

ACKNOWLEDGMENTS	vii
FOREWORD	1
I. INTRODUCTION	3
Atherosclerosis and Arteriosclerosis	3
Significance of Atherosclerosis	5
"Aging-Inevitability" Dogma	9
Method and Purpose of Research	13
II. HUMAN CLINICO-PATHOLOGY: BACKGROUND AND FOUNDATION OF EXPERIMENTAL ATHERO- SCLEROSIS	17
Histo-Pathologic Evidence	17
Biochemico-Pathologic Evidence	18
Ethno-Pathologic Evidence	20
A. Costa Ricans, Chinese, Japanese, American and African Negroes, Kirghiz Plainsmen, Eskimos, Ceylonese, Okinawans	20
B. World Wars I and II	24
C. Under- and Overnutrition	25
D. Diet and Cholesterolemia	32
Clinico-Pathologic Evidence	43
A. Diabetes Mellitus	43
B. The Nephrotic Syndrome	49
C. Hypothyroidism	52
D. Biliary Obstruction	53
E. Essential (Familial) Hypercholesterolemic Xanthomatosis	56
F. Hypertension	59
G. Hyperadrenocorticism	60
H. Coronary Atherosclerosis	61
	xi

III. ATHEROSCLEROSIS AND THE PLASMA LIPOPROTEIN COLLOIDAL COMPLEX (THE STATE OF AGGREGATION OF CHOLESTEROL IN PLASMA)	75
Cholesterol "Solubility"	76
Macromolecular Colloids	76
Alimentary Hyper- and Macrochylomicronemia	86
Total Cholesterol/Lipid Phosphorus Ratio	89
Cholesterol Derivatives	97
Bound and Unbound Cholesterol	98
Classes of Cholesterol-Bearing Lipoprotein Molecules (Ultracentrifuge Studies)	99
Chemical and Electrophoretic Microfractionation of Plasma Proteins and Lipoproteins	113
IV. EXPERIMENTAL ATHEROSCLEROSIS	120
Why the Chick as Experimental Animal?	121
What is the Morphology of Atherosclerosis in the Chick?	124
A. Spontaneous Atherosclerosis	124
B. Cholesterol-induced Atherosclerosis	127
C. Estrogen-induced Atherosclerosis	130
D. Coronary Artery Lesions	131
Are Experimental and Human Lesions Morphologically Similar?	134
Can Quantitative Relationships be Demonstrated between Cholesterol and Atherogenesis?	135
Do Dietary Factors Influence Experimental Atherosclerosis?	143
A. Undernutrition	143
B. Overnutrition	154
C. Neutral Fat Ingestion	155
D. Low-fat Diet	161
E. Vitamins	170
F. Proteins	172
G. Lipotropic Factors	173
H. Agents Possibly Inhibiting Enteric Absorption of Cholesterol	189

CONTENTS

What Endogenous Factors Influence Atherogenesis?	190
A. Thyroid Hormone	190
B. Estrogen and Coronary Atherosclerosis	203
C. Pancreas	208
D. Hypertension	224
E. Pre-existent Vascular Damage	229
F. Vasa Vasorum	233
G. Adrenocorticotrophic and Adrenal Cortical Hormones	233
H. Biliary Obstruction	250
I. Renal Factors	250
J. Age	251
K. Sex	256
L. Species Differences	258
M. Heparin	261
What Experimental Evidence is Available Concern- ing the Influence of Plasma $\frac{\text{Total Cholesterol}}{\text{Lipid Phosphorus}}$ (C/P)	
Ratios on Atherogenesis?	264
Are Atherosclerotic Lesions Reversible?	274
Does Atherosclerosis Develop in Episodic Stages?	279
Can Experimental Atherosclerosis Be Induced with- out Gross Hypercholesterolemia and Organ Lipidosis?	280
V. CONCLUSION	290
BIBLIOGRAPHY	292
AUTHOR INDEX	347
SUBJECT INDEX	363

FOREWORD

"But medicine has long had all its means to hand, and has discovered both a principle and a method, through which the discoveries made over a long period are many and excellent, and through which full discovery will be made, if the enquirer be competent, conduct his researches with knowledge of the discoveries already made, and make them his starting point."

On Ancient Medicine,
A Hippocratic Tract, Author Un-
known, Circa 450 B.C.
Cited by B. Farrington,
Greek Science, Its Meaning for Us
(*Thales to Aristotle*), Penguin
Books, Harmondsworth, Middlesex,
England, 1944.

"Their obscurity [of the internal diseases], however, does not mean that they are our masters, but as far as is possible they have been mastered, a possibility limited only by the capacity of the sick to be examined and of researchers to conduct research. . . .

"When this information is not afforded, and nature herself will yield nothing of her own accord, medicine has found means of compulsion, whereby nature is constrained, without being harmed, to give up her secrets; when these are given up she makes clear to those who understand the art what course ought to be pursued."

The Art,
A Hippocratic Tract, Author Un-
known, Circa 450 B.C.

"Knowledge and Human power are synonymous, since the ignorance of the cause frustrates the effect. . . .

"Now the true and lawful goal of the sciences is none other than this: that human life be endowed with new discoveries and powers."

Novum Organum,
Francis Bacon, 1620.

"'Tis *Works*, not *Words*: *Things*, not *Thinking*: *Pyrotechnic*, not *Philology*: *Operation*, not merely *Speculation*, must justify us Physicians. Forebear then hereafter to be so wrongfully Satirical against our Noble Experimentators, who questionless are entred into the right way of detecting the Truth of things."

George Thomson,
London, 1671.
Cited by B. J. Stern,
Society and Medical Progress,
Princeton University Press, Princeton,
New Jersey, 1941.

I INTRODUCTION

ATHEROSCLEROSIS AND ARTERIOSCLEROSIS

THIS MONOGRAPH DEALS ONLY WITH ATHEROSCLEROSIS. A discussion of other types of arteriosclerosis is beyond its scope.

This subject delineation is not an arbitrary or artificial one. We emphasize the concept that the designation, *arteriosclerosis*, refers to several distinct pathologic entities. It is a generic term. It encompasses a number of different morbid processes, all of which produce thickening of the vessel wall. It includes alterations not necessarily associated with narrowing of the lumen, e.g., Mönckeberg's sclerosis.

When Lobstein first invented the term arteriosclerosis in 1833 (1), he used it precisely in this generic way. In his initial report on medial calcinosis (1903), Mönckeberg stressed that it was a pathologic entity separate and distinct from intimal arteriosclerosis (atherosclerosis) (2). In 1906 Klotz re-posed this problem of definition and classification: "What is arteriosclerosis? (a) is it an entity; or (b) are several distinct morbid conditions included under this one heading . . . ?" (3). He gave a clearcut answer to his question: "Let us preserve the broader meaning, and regard all sclerosis or hardenings of the arteries as included under this general term, recognizing, if need be, distinct varieties" (3).

This view is still maintained by contemporary clinicians, pathologists and experimentalists (4-11). It has been re-enforced by the data of Sappington and Cook (12). These workers studied various types of arteriosclerosis (diffuse in-

timial thickening, Mönckeberg's medial sclerosis, focal intimal atherosclerosis) in the radial, coronary, splenic, renal and cerebral arteries at different ages. Neither Mönckeberg's medial sclerosis nor diffuse intimal thickening was related to the presence or absence of atherosclerosis in the various arterial beds. Boyd recently emphasized such facts and indicated the errors arising from their neglect: "One reason why a perusal of the discussions in the literature is so confusing is that a number of different lesions are included under the one name of arteriosclerosis, so that now one, now another condition is being alluded to. Many authors use the term as synonymous with atheroma. This is quite justifiable as long as the reader is familiar with this usage. It is not really a disease but is rather what Clifford Allbutt calls an omnibus name including several main divisions, the anatomical result of several morbid processes . . . Accordingly we shall not consider the general condition known as hardening of the arteries, but the subject will be divided into three sections: atherosclerosis, Mönckeberg's sclerosis, and diffuse arteriolar sclerosis" (5).

Hueper has recently presented a more detailed breakdown of the various pathologic types of arterial "hardening" (4). Obviously final decision concerning the merit of one or another of these classifications must await more precise elucidation of the pathogenesis and etiology of each process. Nevertheless, sufficient knowledge is currently extant to validate our identifying several distinct entities among the arterioscleroses. And for the sake of clarity the use of the plural term, the arterioscleroses, may not be without value.

In 1904 Marchand coined the term, *atherosclerosis*, to designate the type of intimal arteriosclerosis which is the subject of this monograph (13). The prefix *athero* (Greek *athere*, meaning mush) was selected to designate the amorphous lipid accumulation in the intima which is the hallmark of the developed lesion.